Roth/MKM Starts Tenax Therapeutics (TENX) at Buy, 'Phase 3-Ready Assets to Address Different Types of Pulmonary Hypertension'
Tweet Send to a Friend
(Updated - March 7, 2023 4:48 AM EST)
Roth/MKM analyst Jonathan Aschoff initiates coverage on Tenax Therapeutics (NASDAQ: TENX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Roth/MKM analyst Jonathan Aschoff initiates coverage on Tenax Therapeutics (NASDAQ: TENX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
